ReviewInternational journal of molecular sciences2023

Challenges of CRISPR/Cas-Based Cell Therapy for Type 1 Diabetes: How Not to Engineer a "Trojan Horse".

Dmitry S Karpov et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.